Circulating immune complexes and complement C4 null alleles in patients operated on for premature atherosclerotic peripheral vascular disease

Journal of Clinical Immunology

Volumn 19, Issue 6, 1999, Pages 406-413

  Nityanand, Soniya ^a   Truedsson, Lennart ^b   Mustafa, Awder ^a   Bergmark, Claes ^c   Lefvert, Ann Kari ^a,d  

^a KAROLINSKA INSTITUTE   (Sweden)

^b LUND UNIVERSITY   (Sweden)

^c ST GÖRAN S HOSPITAL   (Sweden)

^d KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Circulating immune complexes; Complement factor C4 deficiency; Peripheral atherosclerosis; Premature atherosclerosis

Indexed keywords

COMPLEMENT COMPONENT C4A; COMPLEMENT COMPONENT C4B;

ADULT; ALLELE; ANTIGEN ANTIBODY COMPLEX; ARTICLE; BLOOD VESSEL INJURY; CONTROLLED STUDY; ELECTROPHORESIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; PERIPHERAL VASCULAR DISEASE; PRIORITY JOURNAL; SUCROSE DENSITY GRADIENT CENTRIFUGATION;

EID: 0033428085     PISSN: 02719142     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1020506901117     Document Type: Article

References (48)

1. 1. Bergmark C, Mansoor MA, Swedenborg J, de Faire U, Svardal AM, Ueland PM: Hyperhomocsyteinemia in patients operated for lower extremity ischaemia below the age of 50: Effect of smoking and extent of disease. Eur J Vasc Surg 7:391-396, 1993
2. 2. Criqui MH, Coughlin SS, Fronek A: Noninvasively diagnosed peripheral arterial disease as a predictor of mortality: Results from a prospective study. Circulation 72:768-773, 1985
3. 3. Davey Smith GH, Shipley MJ, Rose G: Intermittent claudication, heart disease risk factors and mortality. The Whitehall Study. Circulation 82:1025-1031, 1990
4. 4. Hansson GK: Immune and inflammatory mechanisms in the development of atherosclerosis. Br Heart J 69:538-41, 1993
5. 5. Mannik M, Arend WP, Hall AP, Gilliland, BC: Studies on antigen-antibody complexes. I. Elimination of soluble complexes from rabbit circulation. J Exp Med 133:713-739, 1971
6. 6. Wissler RW: Update on the pathogenesis of atherosclerosis. Am J Med 91 (Suppl 1B):2S-9S, 1991
7. 7. Wissler RW, Vesselinovitch D, Ko C: The effects of circulating immune complexes on atherosclerotic lesions in experimental animals and in younger and older humans. Transplant Proc 21:3707-3708, 1989
8. 8. Qiao JH, Castellani LW, Fishbein MC, Lusis AJ: Immune complex mediated vasculitis increase coronary artery lipid accumulation in autoimmune-prone MRL mice. Arterioscler Thromb 13:932-943, 1993
9. 9. Spiera H, Rothenberg RR: Myocardial infarction in four young patients with SLE. J Rheumatol 10:464-466, 1983
10. 10. Fukumoto S, Tsumagari T, Kinjo M, Tanaka K: Coronary atherosclerosis in patients with systemic lupus erythematosus at autopsy. Acta Pathol Jpn 37:1-9, 1987
11. 11. Meller J, Conde CA, Deppisch LM, Donoso E, Dack S: Myocardial infarction due to coronary atherosclerosis in three young adults with systemic lupus erythematosus. Am J Cardiol 35:309-314, 1975
12. 12. Bonfiglio TA, Botti RE, Hagstrom JWC: Coronary arteritis, occlusion and myocardial infarction due to lupus erythematosus. Am Heart J 83:153-158, 1972
13. 13. Schifferli JA, Ng YC, Peters DK: The role of complement and its receptor in the elimination of immune complexes. N Engl J Med 315:488-495, 1984
14. 14. Hauptmann G: Inherited deficiency of the fourth component of human complement. Immunodef Rev 1:3-22, 1988
15. 15. Nityanand S, Dawkins R, Lithell H, Holm G, Lefvert AK: C4 null alleles in a Swedish population. Eur J Immunogenet 22:435-441, 1995
16. 16. Awdeh ZL, Alper CA: Inherited polymorphism of human C4 as revealed by desialyzation. Immunobiology 158:35-41, 1980
17. 17. Zhang WJ, Kay PH, Cobain TJ, Dawkins RL: C4 allotyping on plasma or serum: Application to routine laboratories. Hum Immunol 21:165-171, 1988
18. 18. Mauff G, Alper CA, Awdeh Z, Batchelor JR, Bertrams J Bruun-Petersen, Dawkins RL, et al.: Statement on the nomenclature of human C4 allotypes. Immunobiology 164:184-191, 1983
19. 19. Kramer J, Gyodi E, Fust G: Usefulness of densitometry in typing of human complement component C4. Immunogenetics 29:121-123, 1989
20. 20. Truedsson L, Awdeh Z, Yunis EJ, Mrose S, Moore B, Alper CA: Quantitative variation of C4 variant proteins associated with many MHC haplotypes. Immunogenetics 30:414-421, 1989
21. 21. Nityanand S, Holm G, Lefvert AK: Hepatitis B and C and immune complex mediated vasculitis: Clinical association and the effect of anti-viral treatment. Clin Immunol Immunopathol 82:250-257, 1997
22. 22. Hinton R, Dobrota M: Density gradient centrifugation. In: Work TS, Work E (eds). Laboratory Techniques in Biochemistry and Molecular Biology. Amsterdam, Elsevier/North-Holland, 1978, pp 1-290
23. 23. Truedsson L, Gullstrand B, Jönsson T, Klint C: Serum concentrations of C4 isotypes and factor B in Type 1 C2 deficiency suggest haplotype-dependent quantitative expression of MHC Class III complement genes. Exp Clin Immunogenet 12:66-73, 1995
24. 24. Farrel C, Bloth B, Nielsen H, Daugharty H, Lundman T, Svehag S: A survey for circulating immune complexes in patients with acute myocardial infarction: Use of a C1q-binding assay with soluble protein A as indicator. Scand J Immunol 6:1233-1240, 1977
25. 25. Füst G, Szondy E, Szekely J, Nänai I, Gerö S: Studies on the occurrence of circulating immune complexes in vascular diseases. Atherosclerosis 29:181-190, 1978
26. 26. Szondy E, Mezey Z, Fust G, Szekeley J, Gerö S: Serial measurement of circuating immune complexes in myocardial infarction. Br Heart J 46:93-98, 1981
27. 27. Steffen C, Böhm H, Menzel J: Immune complexes in myocardial infarction. Wien Klin Wochenschr 98:161-165, 1986
28. 28. Leinonen M, Linnanmäki E, Mattila K, Nieminen MS, Valtonen V, Saikku P: Circulating immune complexes containing chlamydial lipopolysaccharide in acute myocardial infarction. Microb Pathogen 9:67-73, 1990
29. 29. Linnanmäki E, Leinonen M, Mattila K, Markku SN, Valtonen V, Saikku P: Chlamydia pneumoniae-specific circulating immune complexes in patients with chronic myocardial infarction. Circulation 87:1130-1134, 1993
30. 30. Lefvert AK, Hamsten A, Holm G: Association between circulating immune complexes, complement C4 null alleles, and myocardial infarction before age 45 years. Arterioscler Thromb Vasc Biol 15:665-668, 1995
31. 31. Law SKA, Dodds AW, Porter RR: A comparison of the properties of two classes, C4A and C4B, of the human complement component C4. EMBO J 3:1819-1823, 1984
32. 32. Isenman DE, Young JR: The molecular basis for the difference in immune haemolysis activity of the Chido and Rodgers isotypes of human complement component C4. J Immunol 132:3019-3027, 1984
33. 33. Bishof NA, Welch TR, Beischel LS: C4B deficiency: A risk factor for bacteremia with encapsulated organisms. JID 162:248-250, 1990
34. 34. Cameron U, Cobain TJ, Zhang WJ, Kay PH, Dawkins RL: Influence of C4 null genes on infection with human immunodeficiency virus. Br Med J 296:1627-1628, 1988
35. 35. Fiueroa JE, Densen P: Infectious diseases associated with complement deficiencies. Clin Microbiol Rev 4:359-395, 1991
36. 36. Cates KL, Densen P, Lockman JC, Levine RP: C4B deficiency is not associated with meningitis or bacteremia with encapsulated bacteria. JID. 165:942-944, 1992
37. 37. Holme E, Cross SJ, Veitch J, O'Neill GJ, Whaley K: Quantitation of human C4A and C4B, in serum and plasma by enzyme-linked immunosorbent assay. Immunogenetics 27:295-297, 1988
38. 38. Dawkins RL, Christiansen FT, Kay PH, Garlepp M, McCluskey JM, Hollingsworth PN, Zilko PJ: Disease association with complotypes, supratypes and haplotypes. Immunol Rev 70:5-22, 1983
39. 39. Alper CA, Awdeh Z, Yunis EJ: Complotypes, extended MHC haplotypes. Exp Clin Immunogenet 9:58-71, 1992
40. 40. Saikku P, Leinonen M, Matilla K, Ekman MR, Nieminen MS, Mäkelä PH, Huttunen JK, Valtonen V: Serological evidence of an association of a novel chlamydia, TWAR, with chronic coronary heart disease and acute myocardial infarction. Lancet 2:983-986, 1988
41. 41. Saikku P, Leinonen M, Tenkanen L, Linnanmäki E, Ekman M-R, Manninen V, Mänttäri M, Frick MH, Huttunen JK: Chronic Chlamydae pneumoniae infection as a risk factor for coronary heart disease in the Helsinki Heart Study. Ann Intern Med 116:273-278, 1992
42. 42. Thom DH, Grayston JT, Siscovick DS, Wang SP, Weiss NS, Daling JR: Association of prior infection with chlamydia pneumoniae and angiographically demonstrated coronary artery disease. JAMA 268:68-72, 1992
43. 43. Kuo CC, Coulson AS, Campbell LA, Cappuccio AL, Lawrence RD, Wang SP, Grayston JT: Detection of chlamydia pneumoniae in atherosclerotic plaques in the walls of arteries of lower extremities from patients undergoing bypass operation for arterial obstruction. J Vasc Surg 26:29-31, 1997
44. 44. Årfors L, Lefvert AK: Enrichment of antibodies against phospholipids in circulating immune complexes in the antiphospholipid syndrome. Clin Exp Immunol 108:47-51, 1997
45. 45. Lopes-Virella MF, Virella G: Immunological and microbiological factors in the pathogenesis of atherosclerosis. Clin Immunol Immunopathol 37:377-386, 1985
46. 46. Höiby N, Döring G, Schiötz PO: Antibody and immune complexes induce tissue factor production by human endothelial cells. J Immunol 40:29-53, 1986
47. 47. Tannenbaum SH, Finko R, Cines DB: Antibody and immune complexes induce tissue factor production by human endothelial cells. J Immunol 137:1532-1537, 1986
48. 48. Nieminen MS, Mattila K, Valtonen V: Infection and inflammation as risk factors for myocardial infarction. Eur Heart J 14 (Suppl K):12-16, 1993